Parkinson Disease Dementia
Conditions
Brief summary
This is a Phase 2 open-label extension study to evaluate the effects of ANAVEX2-73 on safety and efficacy of daily treatment.
Detailed description
This is a Phase 2 open-label extension study to evaluate the effects of ANAVEX2-73 on safety and efficacy of daily treatment.
Interventions
DRUGANAVEX2-73
Oral capsules
Sponsors
Anavex Australia Pty Ltd.
Anavex Germany GmbH
Anavex Life Sciences Corp.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
50 Years to 85 Years
Healthy volunteers
No
Inclusion criteria
* Previous completion of participation in the ANAVEX2-73-PDD-001 study. * Caregivers and subjects (or legal representative) must understand and have signed approved informed consent. * Caregivers and subjects (or legal representative) must be able to understand study requirements and be willing to follow instructions. * Stable regimen of anti-Parkinson's disease medications (including levodopa, dopamine agonists, MAO-B inhibitors, or the COMT inhibitor entacapone), which has been stable for at least 4 weeks prior to Baseline. * Treatment with cholinesterase inhibitor (rivastigmine, donepezil and galantamine (Exelon®, Aricept®, or Reminyl®) will be permitted, provided the dose has been stable for a minimum of 8 weeks prior to joining this study. * Subjects with history of depression on antidepressant medications will be allowed if depression is controlled and they have been on a stable daily dose of the antidepressant for ≥8 weeks before Baseline. * Contraception: Women of childbearing potential must use an acceptable method of contraception starting 4 weeks prior to study drug administration and for a minimum of 4 weeks after study completion. Otherwise, women must be postmenopausal (at least one year absence of vaginal bleeding or spotting) as confirmed by FSH greater than or equal to 40 mIU/mL or 40 IU/L or be surgically sterile. * Men with a potentially fertile partner must have had a vasectomy or be willing to use an acceptable method of contraception for the duration of the study and for 3 months after study drug discontinuation.
Exclusion criteria
* History of any significant neurologic or psychiatric disorder other than PD that can contribute to cognitive impairment. * Any other condition or clinically significant abnormal findings on the physical or neurological examination, medical and psychiatric history, at screening or at baseline that, in the opinion of the Investigator, would make the subject unsuitable for the study. * Potential symptomatic causes of cognitive impairment including but not limited to * abnormal thyroid function test at screening (TSH) * abnormal B12 level at screening * MRI findings (by history) pointing to a potential symptomatic cause of cognitive dysfunction, including significant vascular changes, or communicating hydrocephalus. * Treatment with memantine or amantadine. If appropriate the drugs can be discontinued for a minimum of 4 weeks prior to enrollment. * History of depression as measured by Beck Depression Inventory score \>17 at screening. * Treatment with any other investigational drug or device within 4 weeks prior to screening. * Smoking \> 1 pack of cigarettes per day (as assessed for the 4 weeks prior to screening). * Women who are pregnant or lactating. * Known allergy or sensitivity to ANAVEX2-73 or any of its components. * Suicidal ideation on the Columbia Suicide Severity Rating Scale (C-SSRS) of type 4 or type 5, or any suicidal behavior, in the past 6 months. Type 4 indicates active suicidal ideation with some intent to act, without a specific plan. Type 5 indicates active suicidal ideation with a specific plan and intent. * Use of centrally acting anticholinergic drugs during the 4 weeks before enrollment. * Medications used for overactive bladder will be allowed provided that the regimen has been stable 4 weeks prior to enrollment. * Treatment with any dopamine receptor blocking medications with the exception of low dose quetiapine (≤50 mg/day). Pimavanserin (≤34 mg/day) will be allowed. * History of neurosurgical intervention (e.g., deep brain stimulation) for PD. * Unpredictable motor fluctuations that would interfere with administering cognitive assessments in the ON state.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of participants with treatment-related adverse events as assessed by CTCAE v4.03 | 48 weeks | To continue assessing the safety and tolerability of ANAVEX2-73 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| RSBDQ (REM Sleep Behavior Disorder Screening Questionnaire) | 48 weeks | Change from baseline to End of Treatment as measured by RSBDQ |
| MDS-UPDRS Part III Total Score (Motor Scores) | 48 weeks | Change from baseline to End of Treatment as measured by MDS-UPDRS Part III Total Score (Motor Scores) |
| MoCA (Montreal Cognitive Assessment) | 48 weeks | Change from baseline to End of Treatment as measured by MoCA |
Other
| Measure | Time frame | Description |
|---|---|---|
| Microbiota | 48 weeks | Change from baseline to End of Treatment as measured by microbiota |
Countries
Australia, Spain
Outcome results
None listed